HUP0402259A2 - Vakcinák - Google Patents

Vakcinák

Info

Publication number
HUP0402259A2
HUP0402259A2 HU0402259A HUP0402259A HUP0402259A2 HU P0402259 A2 HUP0402259 A2 HU P0402259A2 HU 0402259 A HU0402259 A HU 0402259A HU P0402259 A HUP0402259 A HU P0402259A HU P0402259 A2 HUP0402259 A2 HU P0402259A2
Authority
HU
Hungary
Prior art keywords
subject
constructs
vaccines
nucleic acid
specifically
Prior art date
Application number
HU0402259A
Other languages
English (en)
Inventor
Andrew Beaton
Peter Franz Ertl
Gerald Wayne Gough
Andrew Lear
John Philip Tite
Catherine Ann Wely
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Publication of HUP0402259A2 publication Critical patent/HUP0402259A2/hu
Publication of HUP0402259A3 publication Critical patent/HUP0402259A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát nukleinsav-konstrukciók, a találmány szerintikonstrukciókat tartalmazó gazdasejtek és a konstrukciók nukleinsavvakcinákban történő alkalmazása képezi. A találmány tárgyát képeziktovábbá, a találmány szerinti konstrukciókat tartalmazóvakcinakészítmények, és a találmány szerinti készítmények alkalmazásaa gyógyászatban. Közelebbről, a találmány tárgyát olyan DNS-vakcinákképezik, amelyek alkalmasak HIV-fertőzések megelőzésére és kezelésére,közelebbről oly módon, hogy bejuttatásuk részecskék alkalmazásávaltörténik. Ó
HU0402259A 2001-09-20 2002-09-18 Vaccines HUP0402259A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines
PCT/EP2002/010592 WO2003025003A2 (en) 2001-09-20 2002-09-18 Hiv-gag codon-optimised dna vaccines

Publications (2)

Publication Number Publication Date
HUP0402259A2 true HUP0402259A2 (hu) 2005-01-28
HUP0402259A3 HUP0402259A3 (en) 2010-01-28

Family

ID=27256076

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402259A HUP0402259A3 (en) 2001-09-20 2002-09-18 Vaccines

Country Status (16)

Country Link
US (2) US20070015721A1 (hu)
EP (2) EP2322626A1 (hu)
JP (1) JP4601956B2 (hu)
CN (1) CN100392085C (hu)
AR (1) AR036566A1 (hu)
AU (1) AU2002362368B2 (hu)
BR (1) BR0212619A (hu)
CA (1) CA2461056A1 (hu)
CO (1) CO5560591A2 (hu)
HU (1) HUP0402259A3 (hu)
IL (1) IL160809A0 (hu)
MX (1) MXPA04002631A (hu)
NO (1) NO331826B1 (hu)
NZ (1) NZ531814A (hu)
PL (1) PL207168B1 (hu)
WO (1) WO2003025003A2 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
US20090208515A1 (en) * 2005-05-12 2009-08-20 Peter Franz Ertl Vaccine composition
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
SI2137210T1 (sl) 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
AR066676A1 (es) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
WO2011043830A2 (en) 2009-10-09 2011-04-14 New York University Methods, agents and peptides for inducing an innate immune response in hiv vaccination
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PL3333265T3 (pl) 2010-05-14 2020-08-10 Oregon Health & Science University Rekombinowane wektory HCMV i RHCMV kodujące heterologiczny antygen wyizolowany z wirusa zapalenia wątroby typu B oraz ich zastosowania
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
CA2955306C (en) 2014-07-16 2021-06-01 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CN108064304A (zh) 2015-02-10 2018-05-22 俄勒冈健康与科学大学 可用于产生非典型cd8+ t细胞应答的方法和组合物
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
EP3529363A4 (en) 2016-10-18 2020-05-06 Oregon Health & Science University CYTOMEGALOVIRUS VECTORS, CALLING OUT T-CELLS, RESTRICTED BY A LARGE HISTOCOMPATIBILITY COMPLEX E-MOLECULE
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU6964191A (en) 1989-11-16 1991-06-13 Cornell Research Foundation Inc. Particle-mediated transformation of animal tissue cells
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
CA2501743C (en) 1994-01-21 2008-11-18 Powderject Vaccines, Inc. Gas driven gene delivery instrument
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
SK112998A3 (en) * 1996-02-22 2000-04-10 Merck & Co Inc Synthetic polynucleotide containing dna sequence being coding hiv env protein, a vaccine with its content and its use
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE10056747A1 (de) * 1999-11-16 2001-05-31 Yiming Shao Das Genom des HIV-1 Intersubtyps (C/B') und seine Anwendungen
CA2393861A1 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1156112B1 (en) * 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization

Also Published As

Publication number Publication date
IL160809A0 (en) 2004-08-31
BR0212619A (pt) 2004-08-17
EP1427826A2 (en) 2004-06-16
HUP0402259A3 (en) 2010-01-28
NO20041157L (no) 2004-05-19
CA2461056A1 (en) 2003-03-27
CN100392085C (zh) 2008-06-04
JP4601956B2 (ja) 2010-12-22
AU2002362368B2 (en) 2006-09-21
JP2005511019A (ja) 2005-04-28
WO2003025003A2 (en) 2003-03-27
US20070015721A1 (en) 2007-01-18
PL370359A1 (en) 2005-05-16
MXPA04002631A (es) 2004-07-08
CO5560591A2 (es) 2005-09-30
NO331826B1 (no) 2012-04-16
AR036566A1 (es) 2004-09-15
PL207168B1 (pl) 2010-11-30
WO2003025003A3 (en) 2003-12-04
EP1427826B1 (en) 2011-04-20
EP2322626A1 (en) 2011-05-18
US20090203144A1 (en) 2009-08-13
CN1606624A (zh) 2005-04-13
NZ531814A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
HUP0402259A2 (hu) Vakcinák
UA88457C2 (ru) Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью
BR0311995A (pt) Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
IL150602A0 (en) Proteosome influenza vaccine
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
HUP0400445A2 (hu) Új vakcinakészítmények
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
HUP0203056A1 (hu) Vakcinakészítmény
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
PT1212358E (pt) Genes sinteticos de papilomavirus humano
Hilleman Immunologic, chemotherapeutic and interferon approaches to control of viral disease
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
EP1316319A4 (en) NOVEL GENE THERAPY AGENT FOR TREATING HEMOPHILIA B AND METHOD FOR PREPARING THE SAME
ATE438714T1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
GB0415437D0 (en) Recombinant virus

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees